Menu
Not yet recruiting NCT07504172

Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity

— Observational Overweight , Obesity Obesity (Disorder)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Tirzepatide.
Who it may be relevant to
Registry conditions: Overweight , Obesity, Obesity (Disorder). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Netherlands
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Real-world Effectiveness and Dosing Patterns of Tirzepatide: A Multicentre Retrospective Observational Study in the Netherlands

Overview

Tirzepatide is one of the new medications for the treatment of obesity. In clinical research people treated with Tirzepatide have weight loss up to 21%. But there is only a little bit of research showing the effect of Tirzepatide in clinical practice. In this retrospective observational study the investigators will evaluate the effectiveness of tirzepatide in routine clinical practice among adults with obesity in the Netherlands.The main questions it aims to answer are: * How much weight do patients lose after six months of treatment with tirzepatide combined with lifestyle coaching? * How is the medication dosed in daily practice? Researchers will use data from electronic health records of patients in multiple outpatient locations of the Dutch Obesity Clinic (NOK, Nederlandse Obesitas Kliniek).

Interventions

  • Drug Tirzepatide
    Initiating treatment with tirzepatide

Primary outcome measures

  • Weight change [Time frame: Baseline-6 months]
Secondary outcome measures (6)
  • Changes in body composition [Time frame: Basline-6 months]
  • Demographic and clinical characteristics [Time frame: Baseline]
  • Weight loss by maintenance dose [Time frame: Baseline-6 months]
  • Tirzepatide dosing patterns [Time frame: Baseline-6 months]
  • Weigth [Time frame: Baseline-6 months]
  • Height [Time frame: Baseline-6 months]

Eligibility criteria

Inclusion criteria

  • Adults (age ≥18 years old)
  • A BMI of ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 with at least one obesity complication (e.g., hypertension, dyslipidaemia)

Exclusion criteria

  • Pregnant women or pregnancy during treatment
  • Previously treated for obesity (with pharmacotherapy, endoscopic treatment or metabolic-bariatric surgery)
  • Patients with diabetes

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Netherlands · 10 centers
  • NOK clinics — Amsterdam
  • NOK clinics — Arnhem
  • NOK clinics — Beverwijk
  • NOK clinics — Gouda
  • NOK clinics — Heerlen
  • NOK clinics — Hoogeveen
  • NOK clinics — Nieuwegein
  • NOK clinics — Terneuzen
  • … and 2 more centers

Publications

  • McGowan B, Ciudin A, Baker JL, Busetto L, Dicker D, Fruhbeck G, Goossens GH, Monami M, Sbraccia P, Martinez-Tellez B, Woodward E, Yumuk V. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med. 2025 Oct;31(10):3317-3329. doi: 10.1038/s41591-025-03978-z. Epub 2025 Oct 2. PMID 41039116
  • Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I; SURMOUNT-1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025 Mar 6;392(10):958-971. doi: 10.1056/NEJMoa2410819. Epub 2024 Nov 13. PMID 39536238
  • Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID 35658024

Identifiers

NCT: NCT07504172 · 202508

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗